GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...
Trump's China tariffs likely to drive up drug prices, spur shortages, experts say
President Donald Trump’s executive order imposing a 10% tariff on Chinese imports is likely to drive up the cost of generic drugs in the United States and exacerbate drug shortages, experts say.
This Chinese MIT Physicist Uses AI To Find New Drugs. Next Up: Solar Panels And EV Batteries
Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...
STAT1d
DeepSeek signals China’s rising influence in AI — and AI drug development
There is growing enthusiasm about China’s potential to speed up drug development with AI. And companies outside the country ...
In China, Rare Dissent Over a Program to Save on Drug Costs
Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.
ophthalmologytimes5d
Vyluma announces NMPA of China accepts drug application of NVK002 (low-dose atropine 0.01%) for myopia progression in children
Zhaoke Ophthalmology Limited is responsible for developing and obtaining regulatory approval for NVK-002 in Greater China, ...
JD Supra1d
China Unveils New Anti-Monopoly Guidelines for the Pharmaceutical Sector
China's State Council issued new Anti-Monopoly Guidelines for the Pharmaceutical Sector (the "Guidelines") effective January 24, 2025. The ...
scmp.com4d
Chinese biotech firms cash in on promising drug discoveries via licensing deals
Licensing deals struck by Chinese biotech ... are conducted and applications are submitted to regulators for marketing approval. Out-licensing typically involves a drug discoverer and patent ...
Vyluma Announces Acceptance of Drug Application for NVK002 by China’s National Medical Products Administration (NMPA)
With its acceptance by the NMPA, NVK002 is now under regulatory review across three major global markets: the United States, the European Union, and China. This milestone reinforces Vyluma’s vision of ...
PharmiWeb8d
Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare for ...